VTE Prophylaxis in the Setting of Cancer

WebCAST CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

November 5, 2008

Expiration Date:

November 5, 2010

Intended Audience:

The educational activity is designed for all physicians, academicians, researchers, investigators, and program directors from the fields of thrombosis, oncology, and haemostasis who manage patients with thrombosis-related disorders, including oncologists, hematologists, coagulation experts, internists, nurse practitioners, and related disciplines.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational
grant from Eisai, Inc.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Craig M. Kessler, MD
Grants/research support: sanofi-aventis, Eisai, GlaxoSmithKline, Octapharma
Consultant: sanofi-aventis, Eisai, NovoNordisk

John Fanikos, RPh, MBA
Speakers Bureau and Consulting: Abbott Laboratories, Astra-Zeneca, Eisai Pharmaceuticals, Genentech, GlaxoSmithKline, sanofi-aventis, The Medicines Company

Samuel Z. Goldhaber, MD
Grant/Research Support: AstraZeneca; Boehringer-Ingelheim; Eisai; GSK; Sanofi-Aventis;
Consultant: Boehringer-Ingelheim; BMS; Eisai; Merck; Pfizer; Sanofi-Aventis

Program Faculty:

Program Chairman
Craig M. Kessler, MD
Professor of Medicine and Pathology
Georgetown University Medical Center
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC

John Fanikos, RPh, MBA
Assistant Director of Pharmacy
Brigham and Women’s Hospital
Assistant Clinical Professor of Pharmacy
Northeastern University
Massachusetts College of Pharmacy
Boston, MA

Samuel Z. Goldhaber, MD
Professor of Medicine
Cardiovascular Division
Harvard Medical School
Director, Venous Thromboembolism Research Unit
Brigham and Women’s Hospital
Boston, MA

Educational Objectives:

Participants in this CME-certified WebCAST will:

• review recent trials, research, and expert analysis of issues focused on thrombosis and cancer.
• learn how national guidelines for thrombosis prevention should impact management of patients with cancer.
• learn strategies for risk-directed prophylaxis against DVT in at risk patients with cancer.
• be able to explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT.
• be able tdo describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis.
• review landmark clinical trials focusing on DVT prophylaxis in patients with cancer.
• be able to explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy.
  
  

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC and CMEducation Resources, LLC. All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved